No Data
Investors Give AIM Vaccine Co., Ltd. (HKG:6660) Shares A 26% Hiding
AIM Vaccine Reduces Losses by Nearly 90% in 2024, With the Iterative Major Product Series Opening up Space for Explosive Growth in Performance
Innovation breakthrough, the king returns, the Aimei vaccine significantly reduced losses by nearly 90%.
When the performance of several major vaccine giants plummeted, the 2024 Earnings Reports released by Aimei Vaccine showed a contrary increase in revenue, reaching 1.285 billion yuan, an increase of 8.2% compared to the previous year. The product sales revenue of hepatitis B vaccine, hepatitis A vaccine, and quadrivalent meningococcal vaccine all showed significant growth. The total loss for the year was 0.278 billion yuan, with a significant narrowing of the net loss by 85.7%, signaling a clear turning point. 1. The adjustment of core product strategy has shown results, with the adult vaccine market becoming a new growth pole that supports the core momentum of performance recovery, with a crucial point reflected in the synergy between the technical barriers of the hepatitis B vaccine product and market strategy.
Aimee Vaccine (06660) achieved revenue of approximately 1.285 billion yuan in 2024, an 8.2% year-on-year growth, with comprehensive breakthroughs in the innovative pipeline.
Aimee Vaccine (06660) announced its 2024 performance, with revenue of approximately 1.285 billion yuan, a year-on-year increase of 8.2%. ...
Express News | AIM Vaccine FY Revenue RMB 1,285 Million
Express News | AIM Vaccine FY Gross Profit RMB 953.5 Million
AIM Vaccine Insider Ups Holding By 649% During Year
